News
Reading time: 5 minutes
States Expand Access to Ivermectin as Cancer Myths Persist
In recent developments, several U.S. states are pushing legislation to broaden access to ivermectin, an antiparasitic drug, amid ongoing unsubstantiated claims of its effectiveness against cancer. This surge coincides with efforts to make the medication available over-the-counter or through easier prescriptions, despite warnings from health experts about misinformation. The Kaiser Family Foundation highlights how these myths have fueled policy changes, potentially impacting public health perceptions. Abortion pill-related false claims have also intertwined with these discussions, complicating the landscape. Critics argue that expanding access without robust evidence could lead to misuse, while supporters cite its established uses in veterinary and human medicine. As of July 2025, monitoring bodies continue to track these trends for safety implications
New Study Backs Ivermectin in Malaria Prevention Efforts
A cluster-randomized trial in Kenya has demonstrated that ivermectin can reduce malaria incidence by 26%, offering new hope for controlling the disease in high-risk areas. Conducted by researchers at the Center for Infectious Disease Research and Policy, the study involved administering the drug to communities, showing significant antiparasitic effects on mosquitoes. This builds on ivermectin's known role in treating river blindness and other parasitic infections. Published in late July 2025, the findings suggest potential integration into mass drug administration programs. However, experts emphasize the need for further large-scale trials to confirm long-term efficacy and safety. Global health organizations are now considering these results for updated malaria strategies. (website-pace.net)
Viagra Shows Promise in Reducing Alzheimer's Risk
Emerging research from Cleveland Clinic indicates that sildenafil, commonly known as Viagra, may lower the risk of Alzheimer's disease by improving brain blood flow and vascular function. A podcast discussion in April 2025 with researcher Feixiong Cheng detailed how the drug's mechanisms could target dementia pathways. This aligns with earlier Oxford University trials showing enhanced cerebral blood vessel activity. While primarily used for erectile dysfunction, these off-label benefits are gaining attention in neurology. Generic versions of sildenafil, which became available after the patent expiration in 2017, offer a more affordable alternative for potential users exploring its neuroprotective effects. Patients are advised to consult physicians before use, as studies are ongoing. The potential repurposing of Viagra could revolutionize preventive care for cognitive decline.
FDA Reviews Nasal Spray Version of Bumetanide for Edema Treatment
The U.S. Food and Drug Administration is set to decide on a new nasal spray formulation of bumetanide, a loop diuretic, for treating edema linked to congestive heart failure, hepatic, and renal diseases, with a decision expected in September 2025. Submitted as RSQ-777, this innovative delivery method aims to provide faster absorption and convenience over traditional tablets. According to updates from medical publications in August 2025, the review process follows positive preliminary data on efficacy. Amid current shortages of bumetanide tablets due to manufacturing issues, this could offer an alternative for patients. Healthcare providers are monitoring supply alerts, which extend into late summer. If approved, it may expand treatment options for fluid retention conditions. (empr.com)
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before starting or changing ED treatment.
For more please contact Edenbridge Customer Service:
Tel: 877-381-EDEN (3336)
Email: sales@edenbridgepharma.com